A Randomized, Double-Blind, Single-Center, Placebo-Controlled Phase 1 Study to Evaluate the Safety, Tolerability, PK and PD of Intravenous DTRI-031 in Healthy Volunteers
Latest Information Update: 23 Mar 2023
At a glance
- Drugs DTRI-031 (Primary)
- Indications Stroke
- Focus Adverse reactions; First in man
- Sponsors Basking Biosciences
- 10 Feb 2023 Results (n=40) presented at the International Stroke Conference 2023.
- 09 Feb 2023 Results published in the Basking Biosciences media release.
- 31 Jan 2023 According to a Basking Biosciences media release, data will be presented at the American Heart Associations 2023 International Stroke Conference (ISC) 2023 held in Dallas, Texas from 8-10th February.